Show simple item record

dc.contributor.authorTanir, Gonul
dc.contributor.authorOzsurekci, Yasemin
dc.contributor.authorLucidarme, Jay
dc.contributor.authorDurmus, Sevgi Yasar
dc.contributor.authorLekshmi, Aiswarya
dc.contributor.authorAkisoglu, Ozlem
dc.contributor.authorAycan, Ahmet Emre
dc.contributor.authorBorrow, Ray
dc.contributor.authorCeyhan, Mehmet
dc.date.accessioned2019-12-10T11:15:20Z
dc.date.available2019-12-10T11:15:20Z
dc.date.issued2018
dc.identifier.issn2164-5515
dc.identifier.urihttps://doi.org/10.1080/21645515.2017.1377380
dc.identifier.urihttp://hdl.handle.net/11655/15209
dc.description.abstractAlthough outbreaks of Neisseria meningitidis serogroup X occured in a couple of African countries, a limited number of serogroup X meningococcal cases were reported in America and Europe as well as Turkey. Additionally, serogroup X is still not represented in current conjugated meningococcal vaccines. Here, we describe the first pediatric case with meningitis caused by Neisseria meningitidis serogroup X ST-5799 (ST-22 complex) that formed a distinct lineage.
dc.language.isoen
dc.publisherTaylor & Francis Inc
dc.relation.isversionof10.1080/21645515.2017.1377380
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBiotechnology & Applied Microbiology
dc.subjectImmunology
dc.titleNeisseria Meningitidis Serogroup X St-5799 (St-22 Complex) In Turkey: A Unique Pediatric Case
dc.typeinfo:eu-repo/semantics/article
dc.relation.journalHuman Vaccines & Immunotherapeutics
dc.contributor.departmentİç Hastalıkları
dc.identifier.volume14
dc.identifier.issue1
dc.identifier.startpage209
dc.identifier.endpage212
dc.description.indexWoS
dc.description.indexScopus


Files in this item

This item appears in the following Collection(s)

Show simple item record